The global oxygen therapy market size accounted for USD 39.51 billion in 2024, grew to USD 41.63 billion in 2025 and is predicted to surpass around USD 66.72 billion by 2034, representing a healthy CAGR of 5.38% between 2024 and 2034. The North America oxygen therapy market size is calculated at USD 13.04 billion in 2024 and is expected to grow at a fastest CAGR of 5.53% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Oxygen Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Oxygen Therapy Market, by Product, 2024-2034
8.1.1 Oxygen Source Equipment
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Oxygen Delivery Devices
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Oxygen Therapy Market, by Portability, 2024-2034
9.1.1. Stationary Oxygen Therapy Equipment Devices
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Portable Oxygen Therapy Equipment Devices
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Oxygen Therapy Market, by Application, 2024-2034
10.1.1. Chronic Obstructive Pulmonary Disease
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Asthma
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Obstructive Sleep Apnea
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Respiratory Distress Syndrome
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Cystic Fibrosis
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Pneumonia
10.1.6.1. Market Revenue and Forecast (2021-2034)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.2. Market Revenue and Forecast, by Portability (2021-2034)
11.1.3. Market Revenue and Forecast, by Application (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Portability (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Portability (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.2. Market Revenue and Forecast, by Portability (2021-2034)
11.2.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Portability (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Portability (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Portability (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Portability (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Application (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.2. Market Revenue and Forecast, by Portability (2021-2034)
11.3.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Portability (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Portability (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Portability (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Portability (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Application (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.2. Market Revenue and Forecast, by Portability (2021-2034)
11.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Portability (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Portability (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Portability (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Portability (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Application (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.2. Market Revenue and Forecast, by Portability (2021-2034)
11.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Portability (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Portability (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.1. Philips Healthcare
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Linde Healthcare
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Chart Industries, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Invacare Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Becton, Dickinson, and Company
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Smiths Medical
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Drägerwerk AG & Co. KGaA
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Teleflex Incorporated
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Fisher & Paykel Healthcare Corporation Limited
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. DeVilbiss Healthcare
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample